

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/428,458

IN THE CLAIMS:

The status of the claims is as follows:

Claims 1-39. (Cancelled).

Claim 40. (Currently Amended) A pharmaceutical composition useful for treating ~~an immunosuppressive disease~~ AIDS, HIV infection or CVI in humans comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of ~~Rp-8-Br-cAMPS,~~ Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claims 41-42. (Cancelled).

Claim 43. (Currently Amended) A method of inhibiting the effects mediated by PKA type I α isozyme comprising administering to a subject in need of said inhibition, a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of ~~Rp-8-Br-cAMPS,~~ Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 44. (Cancelled).

Claim 45. (Currently Amended) A method of treating a subject afflicted with an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI, comprising

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/428,458

administering to said subject a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, ~~sufficient to treat an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type Ia isozyme ($RI\alpha_2C_2$)~~ wherein said cAMP antagonist is a thio-substituted cAMP analog which is an equatorial diastereomer of 8-substituted 3',5'-cyclic adenosine monophosphorothioate (Rp-8-substituted-cAMPS), and wherein said thio-substituted cAMP analog binds to an $RI\alpha$ subunit of said isozyme and acts as a selective or specific antagonist of said isozyme; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claims 46-47. (Cancelled).

Claim 48. (Currently Amended) The method of Claim 47, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS, Rp-piperidino-cAMPS, and Rp-8-Cl-cAMPS.

Claim 49. (Previously Presented) The method of Claim 48, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claims 50-51. (Cancelled).